HC Wainwright Lowers Arcus Biosciences (NYSE:RCUS) Price Target to $18.00

Arcus Biosciences (NYSE:RCUS - Free Report) had its target price lowered by HC Wainwright from $20.00 to $18.00 in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock. HC Wainwright also issued estimates for Arcus Biosciences' Q1 2025 earnings at ($1.30) EPS, Q2 2025 earnings at ($1.10) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($4.69) EPS, FY2026 earnings at ($5.44) EPS, FY2027 earnings at ($5.62) EPS, FY2028 earnings at ($2.81) EPS and FY2029 earnings at ($1.80) EPS.

Other equities research analysts have also recently issued reports about the company. Barclays increased their target price on Arcus Biosciences from $25.00 to $29.00 and gave the stock an "overweight" rating in a research note on Friday, October 25th. Wedbush reissued an "outperform" rating and issued a $36.00 target price on shares of Arcus Biosciences in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $29.50.

Arcus Biosciences Stock Up 3.0 %

Shares of NYSE RCUS traded up $0.32 during trading on Tuesday, reaching $11.06. The company had a trading volume of 1,238,479 shares, compared to its average volume of 894,829. Arcus Biosciences has a 12-month low of $10.63 and a 12-month high of $20.31. The stock has a market cap of $1.01 billion, a PE ratio of -3.51 and a beta of 0.84. The business's 50-day moving average is $14.02 and its 200 day moving average is $15.56. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total value of $53,910.00. Following the transaction, the chief financial officer now owns 60,138 shares of the company's stock, valued at approximately $902,070. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Jane Street Group LLC lifted its holdings in Arcus Biosciences by 59.8% in the third quarter. Jane Street Group LLC now owns 217,041 shares of the company's stock valued at $3,319,000 after acquiring an additional 81,193 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Arcus Biosciences by 11.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company's stock worth $8,669,000 after buying an additional 59,536 shares during the period. GSA Capital Partners LLP raised its stake in shares of Arcus Biosciences by 17.8% in the third quarter. GSA Capital Partners LLP now owns 187,415 shares of the company's stock worth $2,866,000 after buying an additional 28,307 shares during the period. Parkman Healthcare Partners LLC raised its stake in shares of Arcus Biosciences by 146.9% in the third quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company's stock worth $15,684,000 after buying an additional 610,219 shares during the period. Finally, Barclays PLC raised its stake in shares of Arcus Biosciences by 49.0% in the third quarter. Barclays PLC now owns 118,693 shares of the company's stock worth $1,816,000 after buying an additional 39,015 shares during the period. Institutional investors own 92.89% of the company's stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.